News | June 20, 2013

Biosensors Enters Into Licensing Agreement With Eurocor for Drug-Eluting Balloon Range

June 20, 2013 — Biosensors International Group Ltd. has entered into a licensing agreement with Eurocor GmbH, a group company of Opto Circuits (India) Ltd. for their drug eluting balloon (DEB) technology and related intellectual property (IP) rights in relation to the treatment of both coronary and peripheral artery disease. As a first step in this process, an original equipment manufacturer (OEM) arrangement is being implemented, whereby Biosensors will market and sell, under its own brand, DEBs manufactured by Eurocor.

Both agreements will involve three Biosensors-branded DEBs: BioStream; BioPath 014; and BioPath 035. All three devices are drug-eluting balloon dilatation catheters designed for percutaneous transluminal angioplasty (PTA): BioStream has been developed for use in coronary arteries; the two BioPath DEBs have been optimized for the treatment of patients with peripheral arterial disease. BioPath 035 is intended for peripheral intervention above the knee and BioPath 014 for infrapopliteal intervention below the knee.

All three DEBs feature Eurocor’s proprietary coating technology delivering paclitaxel, an antirestenotic drug proven in DEB applications. The coating technology has been proven in several clinical studies performed by Eurocor, including the global Valentine I and II registries. The proprietary coating employed in these DEB products is capable of delivering the antirestenotic drug consistently during very brief inflation times, while also minimizing washout of the drug during delivery and placement of the DEB.

“We are delighted to have acquired a new range of leading DEBs as a result of this licensing agreement with Eurocor,” commented Jeffrey B. Jump, president of Biosensors’ Cardiovascular Division. “These innovative devices will complement our existing portfolio of cardiac stents, and facilitate our entry into the peripheral vascular disease market.”

Following CE mark approval currently anticipated within the next six weeks, BioStream, BioPath 014 and BioPath 035 will be launched in major European markets and selected regions in the Middle East, Africa and Asia. 

“This agreement is further validation for Eurocor’s DEB products. There is considerable scope for global expansion within this rapidly-growing sector of the interventional devices market,” added Dr. Antonino Laudani, COO of Eurocor GmbH.  “We are looking forward to working closely with Biosensors to further the process of establishing Eurocor as one of the leading global providers of innovative DEB products”.

"This arrangement with Eurocor is a positive development in the broadening of our cardiovascular business,” concluded Jack Wang, CEO of Biosensors. “It also marks the first step in our expansion into the peripheral business."

For more infoirmatiuon:

Related Content

An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no statistically significant mortality increase. This was one of the first major reviews of trial data for patients who were treated with a paclitaxel coated device used in peripheral vessels following a meta analysis study of paclitaxel device trials published in December 2018 that showed a mortality safety signal. This was a major discussion during the FDA townhall meeting at the #TCT2019.
News | Drug-Eluting Balloons | October 10, 2019
October 10, 2019 — An independent analysis of Lutonix 035 drug-coated balloon (DCB) patient-level data showed no stat
Virtue Sirolimus-Eluting Balloon Earns FDA Breakthrough Device Designation
News | Drug-Eluting Balloons | September 20, 2019
Orchestra BioMed Inc., in partnership with Terumo Corp. announced the company has secured Breakthrough Device...
SeQuent Please ReX Drug-coated Balloon Catheter Receives FDA Breakthrough Device Designation
News | Drug-Eluting Balloons | August 02, 2019
B. Braun Interventional Systems Inc. (BIS) announced the U.S. Food and Drug Administration (FDA) has granted...
Orchestra BioMed Partnering With Terumo Corp. for Development, Commercialization of Virtue Sirolimus-eluting Balloon
News | Drug-Eluting Balloons | June 13, 2019
Orchestra BioMed Inc. announced it has formed a global strategic partnership with Terumo Corp. for development and...
Philips Shares Three-Year Results for Stellarex .035 Drug-Coated Balloon
News | Drug-Eluting Balloons | May 29, 2019
Philips announced the three-year results from the ILLUMENATE Pivotal trial and the ILLUMENATE European randomized...
Concept Medical Inc. Granted Breakthrough Device Designation for MagicTouch Sirolimus Coated Balloon
News | Drug-Eluting Balloons | May 02, 2019
Concept Medical Inc. (CMI) has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration...
Orchestra BioMed Receives FDA Breakthrough Device Designation for Virtue Sirolimus-eluting Balloon
Technology | Drug-Eluting Balloons | April 24, 2019
Orchestra BioMed Inc. has secured Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) for...
News | Drug-Eluting Balloons | March 06, 2019
Swiss-based M.A. MedAlliance SA has been granted Breakthrough Device Designation from the U.S. Food and Drug...
Philips Releases Three-Year Data on Stellarex Drug-Coated Balloon
News | Drug-Eluting Balloons | January 28, 2019
Philips announced the latest pooled analysis of patient-level data of over 2,300 patients treated with Philips’...
Virtue Sirolimus-Eluting Balloon Demonstrates Positive Safety and Efficacy at Three Years
News | Drug-Eluting Balloons | September 25, 2018
Orchestra BioMed Inc. announced the three-year clinical results from its Sirolimus Angioplasty Balloon for In-Stent...
Overlay Init